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Abstract: This paper introduces a mathematical compartmental formulation of dose-effect synergy
modelling for multiple therapies in non small cell lung cancer (NSCLC): antiangiogenic, immuno-
and radiotherapy. The model formulates the dose-effect relationship in a unified context, with tumor
proliferating rates and necrotic tissue volume progression as a function of therapy management
profiles. The model accounts for inter- and intra-response variability by using surface model
response terms. Slow acting peripheral compartments such as fat and muscle for drug distribution
are not modelled. This minimal pharmacokinetic-pharmacodynamic (PKPD) model is evaluated
with reported data in mice from literature. A systematic analysis is performed by varying only
radiotherapy profiles, while antiangiogenesis and immunotherapy are fixed to their initial profiles.
Three radiotherapy protocols are selected from literature: (1) a single dose 5 Gy once weekly;
(2) a dose of 5 Gy × 3 days followed by a 2 Gy × 3 days after two weeks and (3) a dose of 5 Gy + 2
× 0.075 Gy followed after two weeks by a 2 Gy + 2 × 0.075 Gy dose. A reduction of 28% in tumor
end-volume after 30 days was observed in Protocol 2 when compared to Protocol 1. No changes in
end-volume were observed between Protocol 2 and Protocol 3, this in agreement with other literature
studies. Additional analysis on drug interaction suggested that higher synergy among drugs affects
up to three-fold the tumor volume (increased synergy leads to significantly lower growth ratio and
lower total tumor volume). Similarly, changes in patient response indicated that increased drug
resistance leads to lower reduction rates of tumor volumes, with end-volume increased up to 25–30%.
In conclusion, the proposed minimal PKPD model has physiological value and can be used to study
therapy management protocols and is an aiding tool in the clinical decision making process. Although
developed with data from mice studies, the model is scalable to NSCLC patients.
Keywords: mathematical modelling; lung cancer; mouse data; antiangiogenic therapy; immunotherapy;
radiotherapy; variability; synergy; multiple therapy; anomalous diffusion; fractal kinetics
J. Clin. Med. 2020, 9, 1832; doi:10.3390/jcm9061832 www.mdpi.com/journal/jcm
J. Clin. Med. 2020, 9, 1832 2 of 17
1. Introduction
Drug dosing optimality problem for patient well-being with minimal impact on both economic and
social resources has been recently addressed through multidisciplinarity, as information technology and
computational power have much improved over the past decennia. Computer assisted drug therapy
and long-term management in cancer patients have increased the outcome towards a personalised
approach per individual as the medical information systems can accurately address inter- and
intra-patient variability in response to treatment. A condition thereof is the existence of models to
allow prediction of dose-effect as a function of chosen therapy and management protocol. Ideally, these
models are individualised, hence their structure must go beyond curve fitting based population models.
It has been shown that combination therapy in cancer leads to synergic effects with improved
outcome [1,2]. The SBRT (stereotactic body radiotherapy) is prevalent in lung cancer treatment as it is
most patient friendly in terms of side effects, while proving to have excellent results [3–5]. Combined
with antiangiogenesis and immunotherapy, SBRT could have a significantly improved efficacy.
This paper introduces a minimal model for lung cancer tumor growth prediction as a function
of multiple therapy profiles. Multi-drug therapy results in surface dose-response characteristics,
requiring to revisit the Michael-Mentis relationship [6,7]. Hill curve dose-effect dynamic variability can
account for inter- and intra-patient variability [6,7]. Yet more, beyond the assumption of homogeneity
in drug diffusion pattern in the body, fractal kinetics successfully characterized anomalous diffusion as
a result of tissue heterogeneity in several applications with pharmacological data [8,9]. Latent response
in drug therapy was assumed to be the result of drug trapping, leading to more accurate describing
time-response of bolus administration [10,11].
Continuous dosing strategies are an emerging pattern in cancer treatment, but they require a
prediction model to be used in the optimal cost function (e.g., to maintain tumor volume at a minimal
value) [12,13]. Such strategies are introduced in computer assisted optimal dosing individualised
protocols, where model parameters are identified from available data.
Multiple animal tumor models have been used in the development of chemotherapeutics and
targeted therapies [14]. Similar experimentation led the development of immunotherapies to establish
targeting efficiencies, pharmacokinetics/pharmacodynamics, whether there is spatial heterogeneity
to therapy delivery, and whether therapy presence is related to efficacy. In this study we aimed to
introduce the mathematical model formulation allowing further analysis into multiple therapy and
translation to lung cancer patient data. This is a minimal model based on mouse data from literature
and serves as a tool for further research and integration into a computer assisted optimal cancer
treatment methodology.
2. Materials and Methods
2.1. Antiangiogenesis Therapy
This therapy has been proven to be effective in inhibiting the vascularization of tumor cell
environment, thereby reducing the growth ratio of tumor volume [15,16]. Compared to monotherapy,
combination immunotherapies have proven to significantly improve patient outcome. Several
strategies have been reviewed, with novel strategies focusing on combining anti-angiogenic agents
with chemotherapy or immunotherapy [17].
A realistic tumor growth model defining the tumor dynamics and necrotic tissue part as a result
of antiangiogenesis treatment has been proposed in [18]. The model starts from a minimal formulation
of the tumor growth under Bevacizumab treatment, extended with the volume and dynamics of
the necrotic part and the pharmacodynamics (PD) and mixed-order pharmacokinetics (PK) of the
applied drug.
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The model is described by:
ẋ1 = (a− na)x1 −ba x1x3ED50a+x3
ẋ2 = nax1 +ba
x1x3
ED50a+x3







where x1 represents the proliferating tumor volume (mm3), x2 is the necrotic tumor volume (mm3) and
x3 is the inhibitor serum level (mg/mL) with ua the inhibitor dose rate (mg·day/mL). In this model
representation, a is the tumor growth rate, na is the necrosis rate, ba is the reaction rate coefficient on
the inhibitory effect and ca is the clearance rate on the Michaelis-Menten kinetics x1x3ED50a+x3 (mm
3/day).
The variable bka is the product of variable ba (mg/mL) and rate k (mg·mm3/mL), which is used to
normalize units to allow inhibitor rate input ua in the equation.
This model has been identified in mice for Bevacizumab therapy and values are given in Table 1.
Other values identified for Pegylated Liposomal Doxorubicin are given in [19].
Table 1. Identified averaged values from mice as reported in [18] for Bevacizumab antiangiogenic treatment.
Parameter Name Value Units
a tumor growth rate 0.4579 1/day
ba reaction rate 0.1685 1/day
ca clearance rate 0.1825 1/day
na necrosis rate 0.1030 1/day
bka scaled inhibition rate 1.0839·10−6 mg/(mL·day)
KBa Michaelis-Menten constant (inhibitor) 0.4409 mg/mL
ED50a half-effect concentration 50·10−6 mg/mL
2.2. Immunotherapy
Several types of immunotherapy are used to treat cancer, including immune checkpoint inhibitors,
T-cell transfer therapy, monoclonal antibodies, immune system modulators, to mention a few. For lung
cancer, immune checkpoint inhibitors are used with major breakthrough results, as reported in [20,21],
although in some specific cases this clinical outcome may be limited [22]. Immunotherapy may cause
side-effects such as rash, diarrhea, fatigue, or more rarely, widespread inflammation which leads to
secondary organ effects (cough and chest pains in lung cancer patients). Intravenous administration
of immunotherapy is considered in this study and the treatment can be applied every day, week
or month, in cycles, followed by a rest period to allow recovery and response to immunotherapy.
Although the benefit from this novel therapeutic approach is undeniable, several open questions still
remain unanswered, as summarized in [21].
A model-based assessment of the relationship between Nivolumab exposure and safety was
performed for doses varying from 1 to 10 mg/kg every 2 weeks in non small cell lung cancer (NSCLC)
patients [23]. A previously published PK model was used to analyse the exposure-response in patients
treated with Nivolumab indicating that clearance of drug changes with time, suggesting mixing
heterogeneity and drug trapping. Averaged concentrations of 32± 19*10−3 mg/mL gave efficacy
between 15–18%, with clearance rates varying between 6–18 mL/h (median 11.6 mL/h).
Combinations of 3-drug versus 2-drug immunotherapy increased efficacy from 23% to 53% in
NSCLC patients [24,25]. Pembrolizumab combined with antiangiogenesis therapy, usually Bevacizumab,
it allowed to go to lower doses [26], with efficacy between 19%–43%. In mice, combined therapy provided
up to 50% reduction of growth slope in tumor volumes [27].
Recent studies with Pembrolizumab in clinical trials in patients revealed significant added value
of model based approach to treatment profile management [28]. Concentration-time profiles were
simulated using the established population pharmacokinetic model of Pembrolizumab based on 2993
subjects from five clinical trials across tumor types. Efficacy was analysed by evaluating projections of
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average concentration over the dosing interval (Cavg) and trough concentration (Cmin) at steady state.
Established exposure-response relationships for Pembrolizumab over a 5-fold dose range support that
clinical efficacy and safety of higher single dose profile would be similar to the lower fraction doses
across tumor types. Model based simulation studies in clinical trials for a Nivolumab monotherapy
flat-dosing regimen have been given in [29]. The authors report that the time-averaged steady state
exposure and safety profile of Nivolumab 480 mg every 4 weeks are consistent with that of 3 mg/kg
every 2 weeks across multiple tumor types.
Other model based simulation supported study presenting various flat doses with mg/kg
regimens is given in [30]. A flat dosing is expected to shorten preparation time and improve
ease of administration. Based on population PK modelling, established flat exposure–response
relationships for efficacy and clinical safety, the benefit–risk profile of Nivolumab 240 mg every
2 weeks was comparable to 3 mg/kg every 2 weeks. Such model based analysis is highly relevant,
as the quantitative clinical pharmacology approach provided evidence for regulatory decision-making
on dose modification, obviating the need for an independent clinical study.
Interestingly, model based retrospective studies as reported in [31], indicated that a significant
proportion of advanced NSCLC patients receive Pembrolizumab-based regimens with extended
intervals or delays in routine clinical practice and with similar outcomes to those receiving treatment
at label-specified 3-week intervals.
To summarize, there is evidence to support the need for a PKPD model of combined antiangiogenesis
and immunotherapy and the expectation that such combination therapy models will have great added
value to the community. As detailed in [20], combination therapy of Pembrolizumab and Nivolumab
had significant benefit, the patient characteristic, safety and tolerance should be considered in treatment
decision-making. In this context, the proposed model hereafter includes features such as drug synergy
and patient response to treatment which can be adjusted for further analysis.
2.3. Stereotactic Body Radiotherapy (SBRT)
With the advancement of the changing landscape of lung cancer treatment, radiation therapy
(RT) is the most used modality to address local-regional areas of tissue. RT is a well-known cancer
treatment, with complex and varied toxic biological effects, wanted to be provoked in diseased cells,
while simultaneously avoiding healthy cells [32,33]. Stereotactic body radiation therapy (SBRT) is
an advanced form of hypofractionated RT that consists of precise delivery of higher radiation doses
on precised tumor location [3,15,34,35]. Stereotactic radiation using a linear accelerator has become
a popular treatment for lung cancer. SBRT is an unconventional external beam radiation therapy
designed for very precise tumor localization and radiation delivery. In SBRT, hypofractionated doses
are applied. The principle can be described as follows: high doses of irradiation are delivered in a
single dose or a few treatment fractions, avoiding treating a volume outside of the tumor target [4].
The continually downward bending form of a cell survival can simply be fitted by a second-order
polynomial (i.e., the linear-quadratic (LQ) model), with a zero order constant term to ensure positive
limit at zero dose. Simple radio-biological mechanisms linked to this model, whereas the cell survival
rate is given by [36]:
−ln(S) = αD + βD2
p(survival) = exp(−αD− βD2) (2)
where α and β are coefficients of the fitted linear-quadratic equation, D is the total dose and this
simple LQ formula gives a better description of radiation response in the low-dose region (0–3 Gy).
LQ survival curves are continuously bending with no straight portion either at low or high radiation
doses. The shape (or ‘bendiness’) is determined by the ratio α/β. In the beginning, the use of the LQ
model was conceptually linked to the target-cell hypothesis. However, there is increasing evidence
that many late effects, and even some early effects, of radiation therapy are not directly related to
simple killing of a defined population of target cells [36]. The most prevalent current view is that the
LQ approach represents an approximate, pragmatic method for converting dose–time fractionation
J. Clin. Med. 2020, 9, 1832 5 of 17
schedules into a biologically effective dose. The basic equation for the incomplete repair model for
continuous irradiation is:
E = αD + βD2g (3)
where E is the level of effect, D is the total dose and g is a function of the duration of continuous exposure:
g = 2
µt− 1 + exp(−µt)
(µt)2
(4)
where µ = 0.693T1/2 , with T1/2 (hours) the half time recovery and t (min) duration of exposure. The ratio
α/β = 10 (Gy) is equivalent to the coefficients ratio in the fractionated form of the input:
ur = a0 + a1D + a2Dd + ... (5)
with ai the fraction, D the total dose and d the dose per fraction.
For mouse lung tumor radiation, the ratio α/β ∈ (13, 17) and the effect dose 50% is ED50 ∈
(15, 35) (Gy) for dose rates of (1, 100) (cGy/min). The Equation (2) is a second order polynomial with
inflexion point and limit values, i.e., a sigmoid curve. In practice, only a part of this sigmoid curve is
captured with data, whereas the full form can be computed by the incomplete repair model 3 which
delivers a Hill curve dose-effect relationship [36].
There is evidence to support the claim that combined RT and immunotherapy leads to improved
treatment efficacy [32,37]. Conventional radiotherapy, in addition to its well-established tumoricidal
effects, can also activate the host immune system. Radiation therapy modulates tumor phenotypes,
enhances antigen presentation and tumor immunogenicity, increases production of cytokines and alters
the tumor microenvironment, enabling destruction of the tumor by the immune system. Multisite
SBRT followed by Pembrolizumab was well tolerated with acceptable toxicity and increased overall
survival in several clinical studies in NSCLC patients [38–40]. However, increased treatment efficacy
was observed generally when radiotherapy was combined with immunotherapy in other types of
tumors [37,41].
A recent review of effects of both radiotherapy and immune-checkpoint inhibition is given
in [42]. The authors observe a complex interplay with the innate and adaptive immune systems,
and under certain circumstances, the effects of radiotherapy synergize with those of immune-checkpoint
inhibition to augment the antitumor responses typically observed with either modality alone and
improve clinical outcomes. However, the mechanisms by which radiotherapy and immune-checkpoint
inhibitors synergistically modulate the immune response might also affect both the type and severity
of treatment-related toxicities. This is a line of investigation yet to be pursued. Generally, radiation
promotes the release of danger signals and chemokines that recruit inflammatory cells into the tumor
microenvironment, including antigen-presenting cells that activate cytotoxic T-cell function. By contrast,
radiation can attract immunosuppressive cells into the tumor microenvironment. Sometimes the
antitumor effect of radiotherapy has been observed outside of the radiation field, known as the abscopal
effect, as discussed in [43]. There, the authors highlight new mechanistic explanations for the success or
failure of radiotherapy, and postulate how the combination of immune-modulation and radiation could
tip the balance of the host immune response to promote cure. Furthermore, other studies indicate that
PK uptake may modulate RT effects [44], where tissue heterogeneity due to tumor changes plays an
important role.
2.4. Proposed Combined Therapy Minimal Model
Based on prior evidence summarized above, combining the three therapies in a single PKPD model
representation is conditioned by adequate interpretation of synergistic effects and unit accommodation
across the various inputs. Figure 1 depicts the proposed compartmental PKPD model.
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Figure 1. This is a schematic overview of the PKPD compartmental model.
The proposed minimal PKPD model is given by the set of equations:
ẋ1 = (a− n)x1 −E · x1
ẋ2 = nx1 +E · x1
ẋ3 = −cax3 +ua
ẋe3 = −caxe3 +Eta · x3
ẋ4 = −cix4 +ui
ẋe4 = −cixe4 +Eti · x4
ẋ5 = −crx5 +ur
ẋe5 = −crxe5 +Etr · x5
(6)
with xi expressed in mg/(mL·day). When combined with antiangiogenesis, immunotherapy increases
the therapeutic effect with 25% [1,16,17,45] and up to 50% when combined with radiotherapy [15,34,35,46].





with Etx denoting the interaction between tumor cells and each drug, while Exy denotes interaction
among drugs. When surface models are used to characterize synergic effects among drugs, the effect
drug concentrations xe are normalized to their potency, i.e., to their corresponding half effect
concentration C50. The combined effects of two drugs UA and UB is considered as a new drug,
and expressed as a Hill curve dose-response relationship 3D surface:




with I denoting the interaction term:







the normalized drug effect concentrations and C50 the concentrations
at half effect 50%. The term γ denotes the sigmoidicity of the slope of the Hill surface, which indicates
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a patient drug responsiveness or drug resistance. The term σ denotes the amount of synergy present
between the drugs. In the limits, when either one drug is used, the isobole response has values 0 to 1.
If (8) is preceded by a maximum effect coefficient Emax, usually from 0% to 100% efficacy, then the
effect is expressed in percent. A brief analysis of such surfaces is given in Appendix A.
The coefficients of the proposed model are listed in Table 2.
Table 2. PKPD model coefficients values and units used in this study and the corresponding literature
source. NA denotes source not available. Data from animal studies (mice).
Parameter Name Value Units Source
a tumor growth rate 0.25 1/day [18,46]
n reaction rate 0.10 1/day [18,46]
ca clearance rate Bevacizumab 0.1825 1/day [18]
ci clearance rate Nivolumab 11.6/24 mL/day [23]
cr clearance rate RT 3/24 1/day [36]
C50a half-effect concentration Bevacizumab 0.44 mg/mL [18]
C50i half-effect concentration Nivolumab 32·10−6 mg/mL [23]
C50r half-effect concentration RT 20 Gy/day [36]
C50t half-effect tumor growth 50 % mm3 [36,46]
Emaxa max efficacy Bevacizumab 70 % NA
Emaxi max efficacy Nivolumab 43 % [27]
Emaxr max effect RT 50 % [27,36]
γ patient response/resistance to drug 2.5 (-) [47]
σ drug reaction (synergic) 4 (-) [47]
E combined effects (all) calculated 1/day NA
ua antiangiogenic drug dose rate 0.171 mg/(mL·day) [18]
ui immunotherapy drug dose rate 0.20 mg/(mL·day) [23,27]
ur radiotherapy dose rate varies mg/(mL·day) [46]
The initial tumor volume was fixed at 1000 mm3. The equivalent mass of the tumor from
approximation formula 1 mm3 = 10−3mg [36,46] was used to calibrate radiotherapy model parameters
via a unit transformation from Gy −→ 1/mL. The reported tumor growth volumes are then relative to
their initial value.
2.5. Protocols
The simulation time interval is 30 days, with a 1-day sample interval.
A control test was performed to check the tumor growth evolution without treatment.
The antiangiogenic (AG) therapy from [18] was used, with a 0.171 mg/mL dose applied once
every week. The immunotherapy (IM) from [27] was used, with a 0.2 mg/mL dose applied once every
week (corresponds to a full dose of 10 mg/kg). The doses for ua and ui were not modified throughout
the study from these initial values.
The following RT protocols with values from [14] have been evaluated with the proposed
PKPD model.
Protocol 1: A single dose of 5 Gy once weekly.
Protocol 2: A dose of 5 Gy × 3 days, followed by a 2 Gy × 3 days dose after two weeks.
Protocol 3: A dose of 5 Gy + 2 × 0.075 Gy, followed after 2 weeks by a 2 Gy + 2 × 0.075 Gy dose.
3. Results
The control test result is given in Figure 2. The result corresponds to that given in [18,34,46] and
had the expected qualitatively clinical response [36].
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Figure 2. The total tumor growth volume (blue stems) and corresponding necrotic tumor volume (red
stems) for no treatment.
The profiles for inputs and concentrations for AG and IM drugs are given in Figure 3. These
profiles correspond to literature studies as given in [18,27], respectively. In order to allow a systematic
analysis of the proposed PKPD model, their values and time intervals will remain fixed, allowing to
observe the effect of variation in radiotherapy profiles alone.
Figure 3. The dose rates and concentrations for the antiangiogenesis and immunotherapy drug profiles.
These will remain fixed during the changes in radiotherapy profiles.
The results for Protocol 1 are depicted in Figure 4. As in [46], the single dose had effect as expected
on the tumor growth response. Our profile response was accentuated compared to that in [46] as the
additional antiangiogenesis and immunotherapy synergy was introduced. A 10-fold reduction in the
tumor final volume at the end of the 30 days interval was observed compared to literature.
The results for Protocol 2 are depicted in Figure 5. The response was similar to that of Protocol 1,
but the retardation of tumor growth was somewhat slower in dynamic response, with final volume
at the end of the 30 days interval increased by 28% compared to Protocol 1. This is explained by
lower concentration profiles in the first 15 days compared to Protocol 1, as observed in Figure 5—right.
Similar observations were reported in [28], where protocols of single dose have similar clinical efficacy
as fractionated lower dose protocols (but with same total intake).
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Figure 4. Results obtained for Protocol 1. Left: total tumor growth (blue stems) and necrotic tumor volume
(red stems) response to therapy. Right: radiotherapy profile along with concentration profiles in body.
Figure 5. Results obtained for Protocol 2. Left: total tumor growth (blue stems) and necrotic tumor volume
(red stems) response to therapy. Right: radiotherapy profile along with concentration profiles in body.
The results for Protocol 3 are depicted in Figure 6. There were no changes in the end tumor
volume at the end of the 30 days interval when compared to Protocol 2. However, the retardation
degree of tumor growth was somewhat decreased at the mid-interval as the concentration profile was
lower than in Protocol 2, as observed from Figure 6—right.
Figure 6. Results obtained for Protocol 3. Left: total tumor growth (blue stems) and necrotic tumor volume
(red stems) response to therapy. Right: radiotherapy profile along with concentration profiles in body.
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The systematic analysis is further deployed to capture the effect of drug synergy. For this, Protocol
3 is used. Varying synergy among drugs implies to vary among σ = 1 (almost no synergy) and σ = 8
(significantly high synergy). The simulation results are given in Figure 7 left and right, respectively.
As expected, the tumor volume growth is not much reduced in the no synergy case, whereas in
case of high synergy present, there is a three-fold reduction in final tumor volume at the end of the
30 days interval.
Figure 7. Results obtained for Protocol 3 in tumor growth volume with synergy degree varying from
1 (left) to 8 (right). Red stems denote the active tumor volume and blue stems the total tumor volume.
To complete the systematic analysis of the features included by the proposed PKPD model, let us
consider variations in patient response, i.e., a patient more responding to treatment if γ = 1 and more
resistant to treatment if γ = 8. The drug synergy was set back to its nominal value σ = 4. Protocol
3 is maintained for the radiotherapy profile. The results are given in Figure 8. As expected, if the
patient response to treatment is higher, a pronounced reduction in tumor growth profile is observed.
In presence of drug resistance, we observe an increase in tumor profiles along the 30 days interval with
approximately 25–30%.
Figure 8. Results obtained for Protocol 3 in tumor growth volume with patient response degree varying
from 1 (drug sensitive) to 8 (drug resistant). Red stems denote the active tumor volume and blue stems
the total tumor volume.
J. Clin. Med. 2020, 9, 1832 11 of 17
As a general remark, notice that the long tails observed in effects of RT (or SBRT) in weeks/months
after treatment may be introduced in the model by changing the clearance value for cr; here assumed
to be 3 hours clearance in a day after treatment. This is of course limited for the purpose of the study
to evaluate effects on tumor growth, but a more precise value assignment will give a more realistic
long-term progression of tumor volume.
4. Discussion
The proposed PKPD model is minimal in its description as the number of compartments and
phenomenological dynamics are described at macroscale pathway level. This provides a good
overview of the essential features necessary to be introduced, such as effect sites, isobole surface
models of interaction, degree of synergy among drugs and patient response to treatment (i.e., drug
resistance). Despite its simplicity, the model was able to reproduce qualitatively tumor growth
response to treatment as described in representative studies [14,18,36]. The modelled phenomena was
based on physiological, chemical and molecular reactions described in literature [23–25] and general
observations summarized in reviews [1,16,17,45]. When available, the numerical values introduced
in the model parameters were assumed from literature, as referenced in Table 2. However, several
parameters were not available, so the study introduced variability to assess their effect. The results
suggest this is a fairly sensible model to be further calibrated on experimental data.
Although evaluated with mouse data, the model is directly scalable to diagnosed/treated NSCLC
patients. The advantage of such a minimal PKPD model is that once calibrated for the patient at hand,
hence addressing the personalised medicine concept, it can be used for evaluating various combination
therapies. Reducing stronger drug doses will minimize side effects and incidence for later toxicity,
thereby improving patient tolerance. Exposure–response (E–R) analyses of efficacy and safety can be
used to optimize dosing regimens and establish a benefit–risk profile.
The toxicity and risk of radiation pneumonitis (RP) affecting the healthy tissue in proximity of
tumor volume voxel during RT treatment are not included in this model. This is an important feature
which should not be neglected [48]. The challenge for RT is to balance the high dose to targeted tumor
and the lowest possible dose to organs at risk [49]. A local dose-effect model based on stretched
exponential and power law is proposed in [50]. The model is successfully used to predict RP incidence
in NSCLC treated with SBRT in patients. The model uses a normalized dose and a sigmoidal first order
Hill curve formulation, which could be accommodated in the PKPD formulation of our model after
some adequate transformation. The challenge to be addressed is that the model from [50] describes
phenomenological effects at a different (mezo-)scale than our PKPD model proposed here.
Further yet more complex PKPD models are proposed in literature, describing effects of
combination chemotherapy at micro-scale level [51]. Cooperative binding of transcription factors to
various sites of a gene promoter or the formation of transcription factor multimers can account
for nonlinearity in gene transcription. Inducing conformation changes in proteins, multisite
phosphorylation provides an efficient way to control the catalytic activity of enzymes or the regulatory
activity of transcription factors. The Hill function used to model such activity requires a delayed
negative feedback, known as the Goodwin model [6]. This model can account for bistability oscillatory
modes observed to arise from inhibitory Hill functions with delayed feedback. The implications of
this are significant to model adverse effects with latent manifestation. This part is accounted by the
power-law adaptation in regulatory networks and neural signaling pathways [52]. On the other hand,
the assumption of a kinetic rate constant for the probability of events is not fully correct, for it has
internal states of switching information transcription following fractal patterns [53,54]. The immediate
utility of such observations are the justification of assuming variations in tissue uptake dynamics [9].
The transit times of drug release and absorption are in power-law form, which are the basis for
introducing fractional calculus in modelling pharmacokinetics [8]. The concept of anomalous diffusion
between compartments with different densities is introduced as a generalization of the classical PK
modelling (e.g., central compartment is a fast acting one, while peripheral compartments such as
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muscle, fat, have slower dynamics). Effects of tissue heterogeneity are manifold in terms of dynamic
analysis, an important one being the resident time that a drug remains bound to molecules before
clearance from that compartment. Tissues with heterogeneous density have non-homogeneous drug
distribution, hence drug trapping occurs [11]. This can be modelled in PK compartmental formulation
by adding a memory term, able to characterize long tail dynamics of drug release. Again, the challenge
to accommodate this in our model is the multi-scale pathway.
Tissue heterogeneity in tumor volume changes as a function of cancer cell proliferation, necrosis
and washout, all functions of treatment profiles and drug interaction activity. As heterogeneity
changes, assuming homogeneous drug distribution and uptake is not entirely realistic. Hence, a time
dependent kinetic rate constant needs to be introduced. Furthermore, the patient response to drug
therapy is changing in time as the patient may become drug resistant. This implies changes in
the values for synergy degree σ and patient response γ. Heterogeneity and anomalous perfusion
are observed in post-surgery lung cancer follow up studies [55]. As such, tissue heterogeneity in
lungs has been assessed with maneuverless lung function tests in COPD patients [56,57]. The forced
oscillation technique can be easily introduced to complement the follow up of NSCLC patients during
their treatment as it does not require any forced maneuvers and it only requires tidal breathing
measurement. Combined with CT scan information upon tumor size and local density variations,
the lung function test can be used to provide correlations to the σ and γ model parameters from each
individual measurement over time lapse of patient follow up.
Memory property in biological tissue response is modelled by fractional order derivatives [58],
which can be implemented in efficient numerical computation forms [8]. Several applications of such
descriptors are reviewed in [59]. Furthermore, the model from (2) is a combination of power law
and exponential, which has been already proven mathematically to be fitted by the Mittag-Leffler
function, which is a solution of the fractional derivative [8]. Such models have been shown to fit well
the respiratory tissue properties in COPD [60,61] and other patients [62,63].
5. Conclusions
The paper introduces a minimal PKPD model for drug combination therapy analysis in NSCLC
mice. The model is scalable to NSCLC patients. The drug synergic effects and patient response
variability are introduced in the model by means of surface response models. The model agrees
qualitatively with patho-physiological observations reported in literature. Tools such as PKPD models
enable analysis into multi-drug therapy for NSCLC patients, while their results may reveal information
to obviate the need for independent clinical studies. In view of time, cost and patient-related risks
associated with unique emergency situations (e.g., pandemic outbreak), their relevance in regulatory
decision-making on dose modification becomes crucial.
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Appendix A
Study in the variability of σ and γ parameters for isobole surface response effects is given in [47].
Here we give a summary of variability effects for the three therapies combinations.
The patient response to drug therapy is fixed to γ = 2.5, while the drug interaction synergy degree
varies. The results are depicted in Figure A1 for σ = 0.4, in Figure A2 for σ = 1 and in Figure A3 for
σ = 4.
Figure A1. Surface responses obtained for σ = 0.4 for each drug combination.
Figure A2. Surface responses obtained for σ = 1 for each drug combination.
Figure A3. Surface responses obtained for σ = 4 for each drug combination.
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The drug synergy level is fixed to σ = 1, while the patient response varies from 0.5 < γ < 4.
The results are depicted in Figure A4 for γ = 0.5, in Figure A5 for γ = 1 and in Figure A6 for γ = 4.
Figure A4. Surface responses obtained for γ = 0.5 for each drug combination.
Figure A5. Surface responses obtained for γ = 1 for each drug combination.
Figure A6. Surface responses obtained for γ = 4 for each drug combination.
It can be observed that the surface area variability changes in agreement as expected from changes
in the parameters.
References
1. Mennitto, A.; Huber, V.; Ratta, R.; Sepe, P.; de Braud, F.; Procopio, G.; Guadalupi, V.; Claps, M.; Stellato, M.;
Daveri, E.; et al. Angiogenesis and immunity in renal carcinoma: Can we turn an unhappy relationship into
a happy marriage? J. Clin. Med. 2020, 9, 930.
2. Iafrate, M.; Fruhwirth, G.O. How non-invasive in vivo cell tracking supports the development and translation
of cancer immunotherapies. Front. Physiol. 2020, 11, 154.
3. Liauw, S.; Connell, P.; Weichselbaum, R. New paradigms and future challenges in radiation oncology:
An update of biological targets and technology. Sci. Transl. Med. 2013, 5, 173.
4. Roesch, J.; Andratschke, N.; Guckenberger, M. SBRT in operable early stage lung cancer patients. Transl. Lung
Cancer Res. 2014, 3, 212–224.
5. de Jong, E.; Guckenberger, M.; Andratschke, N.; Dieckmann, K.; Milder, M.; Moller, D.S.; Nyeng, T.B.;
Tanadini-Lang, S.; Lartigau, E.; Lacornerie, T.; et al. Variation in current prescription practice of stereotactic
body radiotherapy for peripherally located early stage non-small cell lung cancer : Recommendations for
prescribing and recording according to the ACROP guideline and ICRU report 91. Radiother. Oncol. 2020,
142, 217–223.
J. Clin. Med. 2020, 9, 1832 15 of 17
6. Gonze, D.; Abou-Jaoude, W. The Goodwin model: Behind the Hill function. PLoS ONE 2013, 8, e69573.
7. Goutelle, S.; Maurin, M.; Rougier, F.; Barbaut, X.; Bourguignon, L.; Ducher, M.; Maire, P. The Hill equation:
A review of its capabilities in pharmacological modelling. Fundam. Clin. Pharmacol. 2008, 22, 633–648.
8. Sopasakis, P.; Sarimveis, H.; Macheras, P.; Dokoumetzidis, A. Fractional calculus in pharmacokinetics.
J. Pharmacokinet. Pharmacodyn. 2018, 45, 107–125.
9. Weiss, M. Comparison of distributed and compartmental models of drug disposition: Assessment of tissue
uptake kinetics. J. Pharmacokinet. Pharmacodyn. 2016, 43, 505–512.
10. Ionescu, C.M.; Copot, D.; De Keyser, R. Modeling doxorubicin effect in various cancer therapies by means
of fractional calculus. In Proceedings of the 2016 American Control Conference (ACC), Boston, MA, USA,
6–8 July 2016; pp. 1283–1288.
11. Copot, D.; Magin, R.; De Keyser, R.; Ionescu, C.M. Data-driven modelling of drug tissue trapping using
anomalous kinetics. Chaos Solitons Fractals 2017, 102, 441–446.
12. Sapi, J.; Kovacs, L.; Drexler, D.A.; Kocsis, P.; Gajari, D.; Sapi, Z. Tumor volume estimation and quasi-continuous
administration for most effective bevacizumab therapy. PLoS ONE 2015, 10, e0142190.
13. Kovacs, L.; Szeles, A.; Sapi, J.; Drexler, D.A.; Rudas, I.; Harmati, I.; Sapi, Z. Model-based angiogenic
inhibition of tumor growth using modern robust control method. Comput. Methods Programs Biomed. 2014,
114, e98–e110.
14. Cekanova, M.; Rathore, K. Animal models and therapeutic molecular targets of cancer, utility and limitations.
Drug Des. Dev. Ther. 2014, 8, 1911–1921.
15. Kim, D.W.N.; Huamani, J.; Niermann, K.J.; Lee, H.; Geng, L.; Leavitt, L.L.; Baheza, R.A.; Jones, C.C.; Tumkur, S.;
Yankeelov, T.E.; et al. Noninvasive assessment of tumor vasculature response to radiation-mediated, vasculature-
targeted therapy using quantified power Doppler Sonography. J. Ultrasound Med. 2006, 25, 1507–1517.
16. Leone, P.; Buonavoglia, A.; Fasano, R.; Solimando, A.G.; De Re, V.; Cicco, S.; Vacca, A.; Racanelli, V. Insights
into the Regulation of Tumor Angiogenesis by Micro-RNAs. J. Clin. Med. 2019, 8, 2030.
17. Teleanu, R.I.; Chircov, C.; Grumezescu, A.M.; Teleanu, D.M. Tumor Angiogenesis and Anti-Angiogenic
Strategies for Cancer Treatment. J. Clin. Med. 2020, 9, 84.
18. Drexler, D.A.; Sapi, J.; Kovacs, L. Modeling of tumor growth incorporating the effects of necrosis and the
effect of bevacizumab. Complexity 2017, 2017, 5985031.
19. Drexler, D.A.; Ferenci, T.; Lovrics A.; Kovacs, L. Modeling of tumor growth incorporating the effect of
pegylated liposomal doxorubicin. In Proceedings of the 2019 IEEE 23rd International Conference on
Intelligent Engineering Systems (INES), Godollo, Hungary, 25–27 April 2019; pp. 369–374.
20. Almutairi, A.R.; Alkhatib, N.; Martin, J.; Babiker, H.M.; Garland, L.L.; McBride, A.; Abraham, I. Comparative
efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced
non-small cell lung cancer: A Bayesian network meta-analysis. Crit. Rev. Oncol. Hematol. 2019, 142, 16–25.
21. Russo, A.R.; McCusker, M.G.; Scilla, K.A.; Arensmeyer, K.E.; Mehra, R.; Adamo, V.; Rolfo, C. Immunotherapy
in Lung Cancer: From a Minor God to the Olympus. In Immunotherapy: Advances in Experimental Medicine
and Biology; Naing A., Hajjar J., Eds.; Springer: Cham, Switzerland, 2020; Volume 1244, pp. 69–92.
22. Pyfferoen, L.; Brabants, E.; Everaert, C.; De Cabooter, N.; Heyns, K.; Deswarte, K.; Vanheerswynghels, M.;
De Prijck, S.; Waegemans, G.; Dullaers, M.; et al. The transcriptome of lung tumor-infiltrating dendritic cells
reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome.
Oncoimmunology 2017, 6, e1253655.
23. Feng, Y.; Wang, X.; Bajaj, G.; Agrawal, S.; Bello, A.; Lestini, B.; Finckestein, F.G.; Park, J.-S.; Roy, A. Nivolumab
exposure-response analyses of efficacy and safety in previously treated squamous and non-squamous
non-small cell lung cancer. Clin. Cancer Res. 2017, 23, 5394–5405.
24. Nikanjam, M.; Patel, H.; Kurzrock, R. Dosing immunotherapy combinations analysis of 3526 patients for
toxicity and response patterns. Oncoimmunology 2017, 6, e1338997.
25. Nikanjam, M.; Liu, S.; Yang, J.; Kurzrock, R. Dosing three-drug combinations that include targeted anti-cancer
agents: Analysis of 37763 patients. Oncologist 2017, 22, 576–584.
26. Renn, A.; Burotto, M.; Rojas, C. Immune checkpoint inhibitor dosing: Can we go lower without compromising
clinical efficacy? J. Glob. Oncol. 2019, 5. doi:10.1200/JGO.19.00142.
27. Capasso, A.; Lang, J.; Pitts, T.M.; Jordan, K.R.; Lieu, C.H.; Davis, S.L.; Diamond, J.R.; Kopetz, S.; Barbee, J.;
Peterson, J.; et al. Characterization of immune responses to anti-PD-1 mono- and combination therapy in
hematopoietic humanized mice implanted with tumor xenographs. J. Immunother. Cancer 2019, 7, 37.
J. Clin. Med. 2020, 9, 1832 16 of 17
28. Lala, M.; Li, T.R.; de Alwis, D.P.; Sinha, V.; Mayawala, K.; Yamamoto, N.; Siu, L.L.; Chartash, E.; Aboshady,
H.; Jain, L. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation
using modelling and simulation. Eur. J. Cancer 2020, 131, 68–75.
29. Long, G.V.; Tykodi, S.S.; Schneider, J.G.; Garbe, C.; Gravis, G.; Rashford, M.; Agrawal, S.; Grigoryeva, E.;
Bello, A.; Roy, A.; et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat
dosing schedule in patients with cancer. Ann. Oncol. 2018, 29, 2208–2213.
30. Zhao, X.; Suryawanshi, S.; Hruska, M.; Feng, Y.; Wang, X.; Shen, J.; Vezina, H.E.; McHenry, M.B.; Waxman, I.M.;
Achanta, A.; et al. Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg
dosing regimen in patients with advanced tumors. Ann. Oncol. 2017, 28, 2002–2008.
31. Sehgal, K.; Bulumulle, A.; Brody, H.; Gill, R.; Macherla, S.; Qilleri, A.; McDonald, D.C.; Cherry, C.R.; Shea, M.;
Huberman, M.S.; et al. Association of extended dosing intervals or delays in pembrolizumab-based regimens
with survival outcomes in advanced non-small cell lung cancer. medRxiv 2020. doi:10.1101/2020.03.31.20048637.
32. Deloch, L.; Deres, A.; Hartman, J.; Frey, B.; Fietkam, R.; Gaipl, U.S. Modern RT concepts and the impact of
radiation on immune activation. Front. Oncol. 2016, 6, 141.
33. Abreu, C.E.C.V.; Ferreira, P.P.R.; de Moraes, F.Y.; Neves, W.F.P.; Godia, R.; Carvalho, H.D.A. Stereotactic body
radiotherapy in lung cancer: An update. J. Bras. Pneumol. 2015, 41, 376–387.
34. Cho, J.; Kodym, R.; Seliounine, S.; Richardson, J.A.; Solberg, T.D.; Story, M.D. High dose-per-fraction
irradiation of limited lung volumes using an image-guided, highly focused irradiator: Simulating stereotactic
body radiotherapy regimens in a small-animal model. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 895–902.
35. Du, S.; Lockamy, V.; Zhou, L.; Xue, C.; LeBlanc, J.; Glenn, S.; Shukla, G.; Yu, Y.; Dicker, A.P.; Leeper, D.B.; et al.
Stereotactic Body Radiation Therapy delivery in a genetically engineered mouse model of lung cancer. Int. J.
Radiat. Oncol. Biol. Phys. 2016, 96, 529–537.
36. Joiner, M.; van der Kogel, A. (Eds.) Basic Clinical Radiobiology, 4th ed.; Hodder Arnold: London, UK, 2009.
37. Bernstein, M.B.; Krishnan, S.; Hodge, J.W.; Chang J.Y. Immunotherapy and stereotactic ablative radiotherapy
(ISABR): A curative approach? Nat. Rev. Clin. Oncol. 2016, 13, 516–524.
38. Theelen, W.S.M.E.; Peulen, H.M.U.; Lalezari, F.; van der Noort, V.; de Vries, J.F.; Aerts, J.G.J.V.; Dumoulin, D.W.;
Bahce, I.; Niemeijer, A.-L.N.; de Langen, A.J.; et al. Effect of Pembrolizumab After Stereotactic Body
Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell
Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019, 5, 1276–1282.
39. Campbell, A.M.; Cai, W.L.; Burkhardt, D.; Gettinger, S.N.; Goldberg, S.B.; Amodio, M.; Kaech, S.;
Krishnaswamy, S.; Decker, R.H. Final Results of a Phase II Prospective Trial Evaluating the Combination
of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic
Non-Small Cell Lung Cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 2019, 105 (Suppl. 1), S36–S37.
40. Schapira, E.; Hubbeling, H.; Yeap, B.Y.; Mehan, W.A.; Shaw, A.T.; Oh, K.; Gainor, J.F.; Shih, H.A.
Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and
Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. Int. J. Radiat. Oncol. Biol. Phys.
2018, 101, 624–629.
41. Luke, J.J.; Lemons, J.M.L.; Karrison, T.G.; Pitroda, S.P.; Melotek, J.M.; Zha, Y.; Al-Hallaq, H.A.; Arina, A.;
Khodarev, N.N.; Janisch, L.; et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic
Body Radiotherapy in Patients With Advanced Solid Tumors. J. Clin. Oncol. 2018, 36, 1611–1618.
42. Hwang, W.L.; Pike, L.R.G.; Royce, T.J.; Mahal, B.A.; Loeffler, J.S. Safety of combining radiotherapy with
immune-checkpoint inhibition. Nat. Rev. Clin. Oncol. 2018, 15, 477–494.
43. Weichselbaum, R.R.; Liang, H.; Deng, L.; Fu, Y.X. Radiotherapy and immunotherapy: A beneficial liaison?
Nat. Rev. Clin. Oncol. 2017, 14, 365–379.
44. Chen, Y.-J.; Tsai, T.-H.; Wang, L.-Y.; Hsieh, C.-H. Local radiotherapy affects the drug PK—Exploration of a
neglected but significant uncertainty in lung cancer therapy. Technol. Cancer Res. Treat. 2017, 16, 705–716.
45. Ren, B.; Rose, J.B.; Liu, Y.; Jaskular-Sztul, R.; Contreras, C.; Beck, A.; Chen, H. Heterogeneity of Vascular
Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine
Tumors. J. Clin. Med. 2019, 8, 1980.
46. Jin, S.Z.; Pan, X.N.; Wu, N.; Jin, G.H.; Liu, S.Z. Whole-body low dose irradiation promotes the efficacy of
conventional radiotherapy for cancer and possible mechanisms. Dose-Response 2007, 5, 349–358.
47. Ionescu, C.M. A computationally efficient Hill curve adaptation strategy during continuous monitoring of
dose-effect relation in anesthesia. Nonlinear Dyn. 2018, 92, 843–852.
J. Clin. Med. 2020, 9, 1832 17 of 17
48. Dhont, J.; Vandemeulebroucke, J.; Burghelea, M.; Poels, K.; Depuydt, T.; Van Den Begin, R.; Jaudet, C.;
Collen, C.; Engels, B.; Reynders, T.; et al. The long- and short-term variability of breathing induced tumor
motion in lung and liver over the course of a radiotherapy treatment. Radiother. Oncol. 2018, 126, 339–346.
49. Vinh-Hung, V.; Leduc, N.; Verellen, D.; Verschraegen, C.; Dipasquale, G.; Nguyen, N.P. The mean absolute
dose deviation—A common metric for the evaluation of dose-volume histograms in radiation therapy.
Med. Dosim. 2019. doi:10.1016/j.meddos.2019.10.004.
50. Selvaraj, J.; Lebesque, J.; Hope, A.; Guckenberger, M.; Werner-Wasik, M.; Peulen, H.; Giuliani, M.; Mantel F.;
Belderbos, J.; Grills, I.; et al. Modelling radiation pneumonitis of pulmonary stereotactic body radiotherapy:
The impact of a local dose-effect relationship for lung perfusion loss. Radiother. Oncol. 2019, 132, 142–147.
51. Curtis, L.T.; van Berkel, V.H.; Frieboes, H.B. Pharmacokinetic/pharmacodynamic modeling of combination
chemotherapy for lung cancer. J. Theor. Biol. 2018, 448, 38–52.
52. Drew, P.J.; Abbott, L.F. Models and properties of power-law adaptation in neural systems. J. Neurophysiol.
2006, 96, 826–833.
53. Liebovitch, L.S.; Scheurle, D.; Rusek, M.; Zochowski, M. Fractal methods to analyze ion channel kinetics.
Methods 2001, 24, 359–375.
54. Ionescu, C.M. Phase Constancy in a Ladder Model of Neural Dynamics. IEEE Trans. Syst. Man Cybern. A
Syst. Hum. 2012, 42, 1543–1551.
55. Holvoet, T.; van Meerbeeck, J.P.; Van de Wiele, C.; Salhi, B.; Derom, E. Quantitative perfusion scintigraphy or
anatomic segment method in lung cancer resection. Lung Cancer 2011, 74, 212–218.
56. Ghita, M.; Copot, D.; Ghita M.; Derom, E.; Ionescu, C.M. Low frequency forced oscillation lung function test
can distinguish dynamic tissue non-linearity in COPD patients. Front. Physiol. 2019, 10, 1390.
57. Copot, D.; De Keyser, R.; Derom, E.; Ionescu, C.M. Structural changes in the COPD lung and related
heterogeneity. PLoS ONE 2017, 12, e0177969.
58. Baleanu, D.; Fernandez, A. On some new properties of fractional derivatives with Mittag-Leffler kernel.
Commun. Nonlinear Sci. Numer. Simul. 2018, 59, 444–462.
59. Ionescu, C.; Lopes, A.; Copot, D.; Machado Tenreiro, J.A.; Bates, J.H.T. The role of fractional calculus in
modeling biological phenomena: A review. Commun. Nonlinear Sci. Numer. Simul. 2017, 51, 141–159.
60. Ionescu, C.; De Keyser, R. Relations between fractional-order model parameters and lung pathology in
chronic obstructive pulmonary disease. IEEE Trans. Biomed. Eng. 2009, 56, 978–987.
61. Ionescu, C.; Derom, E.; De Keyser, R. Assessment of respiratory mechanical properties with constant-phase
models in healthy and COPD lungs. Comput. Methods Programs Biomed. 2010, 97, 78–85.
62. Ionescu, C.M. The Human Respiratory System: An Analysis of the Interplay between Anatomy, Structure, Breathing
and Fractal Dynamics; Springer: London, UK, 2013.
63. Assadi, I.; Charef, A.; Copot, D.; De Keyser, R.; Bensouici, T.; Ionescu, C.M. Evaluation of respiratory
properties by means of fractional order models. Biomed. Signal Process. Control 2017, 34, 206–213.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
